Roanoke Asset Management’s Corcept Therapeutics CORT Stock Holding History

Roanoke Asset Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,000	Closed	-$463K	–	95
2024 Q3	$463K	Hold	10,000	–	–	0.15%	71
2024 Q2	$325K	Hold	10,000	–	–	0.11%	74
2024 Q1	$252K	Hold	10,000	–	–	0.08%	89
2023 Q4	$325K	Hold	10,000	–	–	0.12%	80
2023 Q3	$272K	Hold	10,000	–	–	0.11%	86
2023 Q2	$222K	Hold	10,000	–	–	0.09%	96
2023 Q1	$217K	Sell	10,000 -5,000	-33%	-$110K	0.09%	96
2022 Q4	$305K	Hold	15,000	–	–	0.14%	90
2022 Q3	$385K	Hold	15,000	–	–	0.18%	82
2022 Q2	$357K	Sell	15,000 -5,000	-25%	-$109K	0.16%	84
2022 Q1	$450K	Buy	+20,000	New	+$425K	0.17%	82

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Roanoke Asset Management's CORT Position: Q4 2024 in Review

Roanoke Asset Management sold out of Corcept Therapeutics (CORT) in Q4 2024, closing a stake of 10,000 shares — an estimated $463K sold.

Roanoke Asset Management first reported a position in CORT in Q1 2022 and held it in 11 quarters. The position peaked at $463K in Q3 2024. 367 funds tracked by Wall St. Rank hold CORT as of Q4 2024.

Roanoke Asset Management reported no remaining Corcept Therapeutics position as of Q4 2024 after selling out during the quarter.
Roanoke Asset Management sold 10,000 Corcept Therapeutics shares in Q4 2024, an estimated $463K.
Roanoke Asset Management first reported a position in Corcept Therapeutics in Q1 2022 and held it in 11 quarters.
Roanoke Asset Management's Corcept Therapeutics position peaked at $463K in Q3 2024.
367 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2024.

Based on Roanoke Asset Management's 13F filing for Q4 2024, filed 5 Feb 2025.